Regeneron Eyes 2026 Filing For siRNA Myasthenia Gravis Drug After Phase III Win
Regeneron’s cemdisiran, used alone or in combination with its complement inhibitor Veopoz, significantly improved activities of daily living in patients with generalized myasthenia gravis.Read more:
biospace.comBiotechnology